Celldex Therapeutics Inc (CLDX)

Currency in USD
30.15
+0.65(+2.20%)
Closed·
30.150.00(0.00%)
·
Earnings results expected in 14 days
CLDX is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
29.3330.40
52 wk Range
22.1045.14
Key Statistics
Prev. Close
30.15
Open
29.5
Day's Range
29.33-30.4
52 wk Range
22.1-45.14
Volume
746.58K
Average Vol. (3m)
1.34M
1-Year Change
11.4191%
Book Value / Share
9.10
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
CLDX Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
63.07
Upside
+109.19%
Members' Sentiments
Bearish
Bullish
ProTips
5 analysts have revised their earnings upwards for the upcoming period

Celldex Therapeutics Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy

Analyst Ratings

14 Buy
1 Hold
0 Sell
Ratings:
15 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 63.07
(+109.19% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Morgan Stanley
Buy57.00+89.05%50.00MaintainSep 23, 2026
Stifel
Buy68.00+125.54%-MaintainSep 22, 2026
Morgan Stanley
Buy50.00+65.84%46.00MaintainSep 10, 2026
Barclays
Buy53.00+75.79%48.00MaintainAug 07, 2026
Wells Fargo
Buy72.00+138.81%48.00MaintainJul 29, 2026

Celldex Therapeutics Inc SWOT Analysis


Financial Strength
With $673 million in cash, Celldex is well-funded through 2027, supporting clinical programs and potential commercialization efforts
Market Positioning
Analyst targets range from $30 to $90, with barzolvolimab poised to compete against established treatments like Xolair in the lucrative CSU market
Pipeline Expansion
Delve into CDX-622, Celldex's bispecific program targeting TSLP and SCF, opening new frontiers in asthma and food allergy treatment
Barzolvolimab's Promise
Explore Celldex's lead candidate barzolvolimab, showing remarkable efficacy in treating chronic spontaneous urticaria with potential for $1 billion peak sales
Read full SWOT analysis

Earnings

Latest Release
Aug 06, 2026
EPS / Forecast
-0.94 / -1.06
Revenue / Forecast
22K / 802.64K
EPS Revisions
Last 90 days

CLDX Income Statement

Compare CLDX to Peers and Sector

Metrics to compare
CLDX
Peers
Sector
Relationship
P/E Ratio
−7.9x−1.9x−0.3x
PEG Ratio
0.18−0.060.00
Price / Book
3.3x1.0x2.6x
Price / LTM Sales
14,985.2x54.7x2.9x
Upside (Analyst Target)
109.2%284.6%64.0%
Fair Value Upside
Unlock22.0%9.7%Unlock

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company’s drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. It develops clinical programs, including Barzolvolimab (CDX-0159), a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity for treating chronic urticarias, prurigo nodularis, eosinophilic esophagitis, and atopic dermatitis; and CDX-622, a bispecific candidate for inflammatory diseases, which targets two complementary pathways that drive chronic inflammation, potently neutralizing the alarmin thymic stromal lymphopoietin and depleting mast cells through stem cell factor starvation. Celldex Therapeutics, Inc. is headquartered in Hampton, New Jersey.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
37.64M47.93%1.11B
Other Institutional Investors
59.31M52.07%1.75B
Public Companies & Retail Investors
0.000.00%0.00
Total
96.94M100.00%2.86B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Wellington Management Group LLP12.15%9,543,671281,538
FMR LLC10.71%8,410,828248,119

People Also Watch

91.320
KOD
+1.92%
119.31
CBRS
+10.10%
167.43
CRDO
+10.77%
67.12
AMBA
+0.45%
24.890
VKTX
+2.81%

FAQ

What Is the Celldex Therapeutics (CLDX) Stock Price Today?

The Celldex Therapeutics stock price today is 30.15 USD.

What Stock Exchange Does Celldex Therapeutics Trade On?

Celldex Therapeutics is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Celldex Therapeutics?

The stock symbol for Celldex Therapeutics is "CLDX."

What Is the Celldex Therapeutics Market Cap?

As of today, Celldex Therapeutics market cap is 2.37B USD.

What Is Celldex Therapeutics's Earnings Per Share (TTM)?

The Celldex Therapeutics EPS (TTM) is -4.33.

When Is the Next Celldex Therapeutics Earnings Date?

Celldex Therapeutics will release its next earnings report on Nov 11, 2026.

From a Technical Analysis Perspective, Is CLDX a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.

How Many Times Has Celldex Therapeutics Stock Split?

Celldex Therapeutics has split 2 times.

How Many Employees Does Celldex Therapeutics Have?

Celldex Therapeutics has 198 employees.

What is the current trading status of Celldex Therapeutics (CLDX)?

As of Oct 28, 2026, Celldex Therapeutics (CLDX) is trading at a price of 30.15 USD, with a previous close of 30.15 USD. The stock has fluctuated within a day range of 29.33 USD to 30.40 USD, while its 52-week range spans from 22.10 USD to 45.14 USD.

What Is Celldex Therapeutics (CLDX) Price Target According to Analysts?

The average 12-month price target for Celldex Therapeutics is 63.07 USD, with a high estimate of 100 USD and a low estimate of 28 USD. 14 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +109.19% Upside potential.

What Is the CLDX Premarket Price?

CLDX's last pre-market stock price is 28.65 USD. The pre-market share volume is 290.00, and the stock has decreased by -0.85, or -2.88%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.